AR102562A1 - Métodos para tratar la enfermedad de huntington usando composiciones de cisteamina - Google Patents
Métodos para tratar la enfermedad de huntington usando composiciones de cisteaminaInfo
- Publication number
- AR102562A1 AR102562A1 ARP150103610A ARP150103610A AR102562A1 AR 102562 A1 AR102562 A1 AR 102562A1 AR P150103610 A ARP150103610 A AR P150103610A AR P150103610 A ARP150103610 A AR P150103610A AR 102562 A1 AR102562 A1 AR 102562A1
- Authority
- AR
- Argentina
- Prior art keywords
- bdnf
- disease
- compositions
- methods
- cisteamine
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000023105 Huntington disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 abstract 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 abstract 2
- 102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 abstract 2
- 108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 abstract 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 abstract 1
- 102000018899 Glutamate Receptors Human genes 0.000 abstract 1
- 108010027915 Glutamate Receptors Proteins 0.000 abstract 1
- 101150056950 Ntrk2 gene Proteins 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 229940005529 antipsychotics Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 abstract 1
- 229940099500 cystamine Drugs 0.000 abstract 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 229960004577 laquinimod Drugs 0.000 abstract 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 abstract 1
- 229960003151 mercaptamine Drugs 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960005333 tetrabenazine Drugs 0.000 abstract 1
- 102000015534 trkB Receptor Human genes 0.000 abstract 1
- 108010064880 trkB Receptor Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Métodos para el tratamiento de enfermedades neurodegenerativas, tales como la Enfermedad de Huntington, usando composiciones que comprenden cisteamina o cistamina o sales o derivados de las mismas. Reivindicación 11: El método de acuerdo con la reivindicación 10, caracterizado porque la terapia adjunta se selecciona del grupo que consiste en una terapia a base de antipsicóticos, de antidepresivos, de inhibidores de los transportadores de monoaminas vesiculares (VMAT), tales como la tetrabenazina, de inhibidores de la dopamina, de laquinimod, de inmunomoduladores del SNC, de factores neuroprotectores, del BDNF, de agentes útiles para incrementar la actividad del BDNF, de ampaquinas, de moduladores positivos de los receptores del glutamato del tipo del AMPA o de activadores de los receptores del BDNF del tipo de TrkB, y una terapia génica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462075536P | 2014-11-05 | 2014-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102562A1 true AR102562A1 (es) | 2017-03-08 |
Family
ID=55909803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103610A AR102562A1 (es) | 2014-11-05 | 2015-11-05 | Métodos para tratar la enfermedad de huntington usando composiciones de cisteamina |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20160128954A1 (es) |
| EP (1) | EP3215222A4 (es) |
| JP (1) | JP2017533967A (es) |
| CN (1) | CN107106875A (es) |
| AR (1) | AR102562A1 (es) |
| AU (1) | AU2015343060A1 (es) |
| BR (1) | BR112017009448A2 (es) |
| CA (1) | CA2966879A1 (es) |
| TW (1) | TW201618760A (es) |
| WO (1) | WO2016073716A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017161318A1 (en) | 2016-03-17 | 2017-09-21 | Thiogenesis Therapeutics, Inc. | Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders |
| WO2019060634A1 (en) * | 2017-09-20 | 2019-03-28 | Thiogenesis Therapeutics, Inc. | METHODS OF TREATING CYSTEAMINE SENSITIVE DISORDERS |
| US12391643B2 (en) | 2019-03-26 | 2025-08-19 | The Regents Of The University Of California | Substituted amino-thiol and amino-disulfide compounds, and uses thereof |
| JP7436524B2 (ja) * | 2019-06-12 | 2024-02-21 | プリレニア ニューロセラピューティクス リミテッド | ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2774755T3 (es) * | 2006-01-27 | 2020-07-22 | Univ California | Cisteamina con recubrimiento entérico, cistamina y derivados de las mismas |
| US20120309785A1 (en) * | 2010-12-03 | 2012-12-06 | Bill Piu Chan | Use of Cysteamine in Treating Parkinson's Disease |
| CA2732440C (en) * | 2011-02-23 | 2017-10-31 | Universite Laval | Cystamine analogues for the treatment of parkinson`s disease |
-
2015
- 2015-11-04 TW TW104136399A patent/TW201618760A/zh unknown
- 2015-11-05 WO PCT/US2015/059239 patent/WO2016073716A1/en not_active Ceased
- 2015-11-05 AU AU2015343060A patent/AU2015343060A1/en not_active Abandoned
- 2015-11-05 JP JP2017544287A patent/JP2017533967A/ja active Pending
- 2015-11-05 CA CA2966879A patent/CA2966879A1/en not_active Abandoned
- 2015-11-05 CN CN201580071440.9A patent/CN107106875A/zh active Pending
- 2015-11-05 EP EP15857339.4A patent/EP3215222A4/en not_active Withdrawn
- 2015-11-05 US US14/933,529 patent/US20160128954A1/en not_active Abandoned
- 2015-11-05 AR ARP150103610A patent/AR102562A1/es unknown
- 2015-11-05 BR BR112017009448A patent/BR112017009448A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN107106875A (zh) | 2017-08-29 |
| US20160128954A1 (en) | 2016-05-12 |
| TW201618760A (zh) | 2016-06-01 |
| AU2015343060A1 (en) | 2017-05-25 |
| BR112017009448A2 (pt) | 2017-12-19 |
| EP3215222A4 (en) | 2018-06-13 |
| EP3215222A1 (en) | 2017-09-13 |
| CA2966879A1 (en) | 2016-05-12 |
| WO2016073716A1 (en) | 2016-05-12 |
| JP2017533967A (ja) | 2017-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501046A1 (en) | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases | |
| CO2018005640A2 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
| MX2018010100A (es) | Metodos para usar agonistas de fxr. | |
| MX2017016344A (es) | Compuestos de benzoxacepina oxazolidinona y metodos de uso. | |
| CR20190318A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX2019010541A (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| MX2020010999A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. | |
| BR112017011923A2 (pt) | bactéria modificada para tratar doenças associadas com hiperamonemia | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| MX2016014253A (es) | Inhibidores de desmetilasa-1 especifica de lisina. | |
| MX2017007664A (es) | Derivados de 2-anilinopirimidina sustituida como moduladores de egfr. | |
| DOP2016000194A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| MX2018011785A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue. | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| CO2018007278A2 (es) | Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan | |
| MX2019003026A (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
| MX2021003110A (es) | Agonistas del receptor x farnesoide y usos de los mismos. | |
| MX392523B (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar | |
| AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| CL2021000329A1 (es) | Compuestos útiles en terapia del vih | |
| CU20160140A7 (es) | CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA | |
| UY36124A (es) | Derivados de carboxamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |